Russell Investments Group Ltd. Has $2.53 Million Stock Position in Xenon Pharmaceuticals Inc. $XENE

Key Points

• Russell Investments Group Ltd. has decreased its stake in Xenon Pharmaceuticals Inc. by 64.7% to $2.53 million, owning 75,341 shares after selling 138,355 during the first quarter.
• Xenon Pharmaceuticals reported a loss of ($1.07) earnings per share for the latest quarter, missing analysts' expectations by $0.04.
• The stock has received mixed ratings from analysts, with a consensus rating of "Buy" and an average price target of $53.20.

Russell Investments Group Ltd. lowered its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 64.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 75,341 shares of the biopharmaceutical company's stock after selling 138,355 shares during the quarter. Russell Investments Group Ltd. owned 0.10% of Xenon Pharmaceuticals worth $2,528,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of XENE. GF Fund Management CO. LTD. bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $63,000. Quarry LP bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $78,000. Vident Advisory LLC bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $212,000. Tema Etfs LLC bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $240,000. Finally, Legato Capital Management LLC bought a new stake in shares of Xenon Pharmaceuticals during the 1st quarter worth approximately $323,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Xenon Pharmaceuticals Trading Up 1.7%

XENE opened at $38.84 on Monday. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $46.00. The stock's fifty day simple moving average is $33.16 and its 200 day simple moving average is $33.91. The stock has a market cap of $2.99 billion, a PE ratio of -10.94 and a beta of 1.16.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period in the previous year, the company posted ($0.75) earnings per share. Equities analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Wall Street Zen cut Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Wedbush upped their price objective on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 12th. William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Monday, May 5th. Royal Bank Of Canada dropped their price target on Xenon Pharmaceuticals from $57.00 to $55.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 12th. Finally, HC Wainwright restated a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, May 13th. Eleven analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $53.20.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.